BioCores: identification of a drug/natural product-based privileged structural motif for small-molecule lead discovery

@article{Kombarov2009BioCoresIO,
  title={BioCores: identification of a drug/natural product-based privileged structural motif for small-molecule lead discovery},
  author={Roman V. Kombarov and Andrea Altieri and Dmitry Genis and Mikhail Kirpichenok and Valeriy Kochubey and Natalia Rakitina and Zoya Titarenko},
  journal={Molecular Diversity},
  year={2009},
  volume={14},
  pages={193-200}
}
The analysis of known drugs (Comprehensive Medicinal Chemistry database (2008 version): http://www.mdl.com/products/knowledge/medicinal_chem/index.jsp) and natural products (Koch et al., Proc Natl Acad Sci USA 102:17272–17277, 2008) has led to the identification of privileged saturated and aromatic heterocyclic ring pairs that we have termed as “BioCores.” This article explains how the BioCores can be used for the design of novel lead-like scaffolds. 
A minimalist fragment approach for the design of natural-product-like synthetic scaffolds.
TLDR
This article outlines the recent approaches in this area and suggests a simple metric to assess synthetic compounds for natural product likeness, which could be used to assess 'biological appropriateness' of these compounds. Expand
Natural product-like synthetic libraries.
TLDR
There is a paucity of chemical matter suitably poised for effective drug development and in the absence of specific molecular information that can be modeled and used predicatively the authors are far from identifying which small molecules are most relevant to emerging biological targets such as protein-protein interactions. Expand
Smart Design of Small‐Molecule Libraries: When Organic Synthesis Meets Cheminformatics
  • E. Lenci, A. Trabocchi
  • Medicine, Computer Science
  • Chembiochem : a European journal of chemical biology
  • 2019
TLDR
This minireview focuses on novel cheminformatics approaches used to design molecular scaffolds, as well as to analyze their quality, giving a perspective of them in the field of chemical biology and drug discovery through some selected case studies. Expand
Privileged Structures and Motifs (Synthetic and Natural Scaffolds)
In the constantly evolving world of drug discovery, there remains a constant: the privileged structure. In this article, we define and review the concept of the privileged structure. We focus on itsExpand
Discovery and Development of Lead Compounds from Natural Sources Using Computational Approaches
TLDR
The synergy between natural product-based drug discovery and methods used in computer-aided drug design and computational methods are discussed, making significant contributions to identifying and developing bioactive compounds of therapeutic relevance. Expand
Toward an Efficient Approach to Identify Molecular Scaffolds Possessing Selective or Promiscuous Compounds
TLDR
A scaffold analysis of compounds screened across 100 sequence‐unrelated proteins to identify scaffolds that drive promiscuity or selectivity is presented and can be applied to any other data sets and activity readout. Expand
Combining Molecular Scaffolds from FDA Approved Drugs: Application to Drug Discovery.
TLDR
It is found that less than 1% of the possible combinations of drug ring systems appear in commercially available libraries, which highlights significant opportunities to design new fragment-like and lead-like libraries aimed at improving success rates and reducing risk in small molecule drug discovery. Expand
Bicyclic acetals: biological relevance, scaffold analysis, and applications in diversity-oriented synthesis.
TLDR
A summary of some recent efforts on the development of acetal-containing small molecule collections through DOS approaches is reported, highlighting the great potential of bicyclic acetals in Diversity-Oriented Synthesis (DOS). Expand
Natural products as platforms for the design of sphingolipid-related anticancer agents.
TLDR
The aim of this chapter is to provide the reader with a general overview of some of the most representative families of sphingolipid-related natural products that have been described in the recent literature as lead compounds for the design of new modulators ofSphingolIPid metabolism. Expand
Molecular Scaffold Analysis of Natural Products Databases in the Public Domain
TLDR
It was found that publicly available natural products databases have different scaffold diversity, and in contrast to the common concept that larger libraries have the largest scaffold Diversity, the largest natural products collection analyzed in this work was not the most diverse. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Natural compounds as drugs
TLDR
This work describes Artemisinin - an innovative cornerstone for anti-malaria therapy and chemical-genetic approaches for exploring the mode of action of natural products. Expand
Charting biologically relevant chemical space: a structural classification of natural products (SCONP).
TLDR
A structural classification of natural products (SCONP) is reported as organizing principle for charting the known chemical space explored by nature and provides a viable analysis- and hypothesis-generating tool for the design of natural product-derived compound collections. Expand
Novel chemical space exploration via natural products.
TLDR
The chemical space navigation tool ChemGPS-NP is used to evaluate the chemical space occupancy by NPs and bioactive medicinal chemistry compounds from the database WOMBAT and property based similarity calculations were performed to identify NP neighbors of approved drugs. Expand
The role of natural product chemistry in drug discovery.
  • M. Butler
  • Medicine
  • Journal of natural products
  • 2004
TLDR
To continue to be competitive with other drug discovery methods, natural product research needs to continually improve the speed of the screening, isolation, and structure elucidation processes, as well addressing the suitability of screens for natural product extracts and dealing with issues involved with large-scale compound supply. Expand
The properties of known drugs. 1. Molecular frameworks.
TLDR
This work uses shape description methods to analyze a database of commercially available drugs and prepares a list of common drug shapes, finding that the diversity of shapes in the set of known drugs is extremely low. Expand
Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening.
  • G. Rishton
  • Biology, Medicine
  • Current opinion in chemical biology
  • 2008
TLDR
The benefits of leadlikeness in the biochemical screening arena (including fragment-based screening and co-crystallization studies) are described here and recommendations are forwarded for the generation of leadlike molecular diversity. Expand
Design of Array-Type Compound Libraries that Combine Information from Natural Products and Synthetic Molecules
TLDR
The design principles and organization of MetaFocus (MF) arrays are introduced and example applications are presented to serve as a knowledge base for drug discovery applications. Expand
Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection.
TLDR
The NIBR compound collection enrichment and enhancement project integrates corporate internal combinatorial compound synthesis and external compound acquisition activities in order to build up a comprehensive screening collection for a modern drug discovery organization. Expand
Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry
TLDR
It is suggested that by mimicking certain distribution properties of natural compounds, combinatorial products might be made that are substantially more diverse and have greater biological relevance. Expand
Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.
TLDR
A combination of structural fragment counts, termed the "2-0" kinase-likeness rule, provides approximately 5-fold enrichment in kinase active compounds, and has been validated using in-house kinase counterscreening data and applied prospectively to uncover kinase activities in marketed drugs. Expand
...
1
2
...